Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Targeted cancer therapies.

Jean-Yves Blay1, Axel Le Cesne, Laurent Alberti

  • 1Inserm Unit 590, Centre Leon Berard, 28 rue Laennec, 69008 Lyon, France. blay@fnclcc.lyon.fr

Bulletin Du Cancer
|March 8, 2005
PubMed
Summary

Targeted cancer therapies inhibit oncogenes driving cancer. Therapies targeting early oncogenes show high response rates, while those targeting later-stage oncogenes are more effective with chemotherapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

MiT fusions, TSC1-TSC2 divergence, and stem-like programs reveal distinct origins and vulnerabilities in PEComa.

Nature communications·2026
Same author

A pooled analysis of phase 2 clinical trials in advanced chordoma.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Overall survival of patients with localized soft tissue sarcoma treated with or without adjuvant chemotherapy (DEEPSARC): a real world nationwide retrospective cohort study in France.

EClinicalMedicine·2026
Same author

Deep Learning Predicts Mutations and Outcomes in Gastrointestinal Stromal Tumors from Whole-Slide Images.

Cancer research·2026
Same author

Metastatic Ewing Sarcoma, Patterns of Care and Outcomes of Patients in a Real-Life National Setting Over a Decade.

Cancer medicine·2026
Same author

Characteristics and outcome of intra-abdominal desmoid-type fibromatosis.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2026

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Targeted cancer therapies aim to inhibit oncogene products crucial for neoplastic transformation.
  • These therapies are categorized based on the oncogene's role in cancer development: initiation or progression.

Purpose of the Study:

  • To review examples of targeted cancer therapies and their clinical outcomes.
  • To differentiate the efficacy of targeted therapies based on their molecular targets' roles in cancer.

Main Methods:

  • Review of existing literature and clinical data on targeted cancer therapies.
  • Analysis of treatment responses in relation to oncogene involvement (initiation vs. progression).

Main Results:

  • Targeted therapies against early-stage oncogenes (e.g., imatinib for CML/GIST) demonstrate high response rates as single agents.
  • Therapies targeting later-stage oncogenes (e.g., trastuzumab for HER2+ breast cancer) show lower response rates alone but synergize with chemotherapy.
  • No efficacy observed when targeted therapies are used on tumors where the target is not causally involved in transformation.

Conclusions:

  • The efficacy of targeted cancer therapies is strongly dependent on the oncogene's specific role in neoplastic transformation.
  • Identifying specific mutations (e.g., HER1 in lung cancer) can define new patient subgroups responsive to targeted treatments.
  • Targeted therapies represent a significant advancement in personalized cancer treatment strategies.

Related Experiment Videos